A detailed history of Marshall Wace, LLP transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 33,777 shares of FLGT stock, worth $660,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,777
Holding current value
$660,340
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.6 - $25.06 $662,029 - $846,451
33,777 New
33,777 $733,000
Q4 2023

Feb 14, 2024

BUY
$23.64 - $30.27 $70,163 - $89,841
2,968 Added 23.5%
15,600 $450,000
Q3 2023

Nov 14, 2023

BUY
$26.74 - $40.81 $171,563 - $261,836
6,416 Added 103.22%
12,632 $337,000
Q2 2023

Aug 14, 2023

BUY
$28.52 - $40.7 $177,280 - $252,991
6,216 New
6,216 $230,000
Q4 2022

Feb 14, 2023

SELL
$29.23 - $40.28 $1.44 Million - $1.98 Million
-49,109 Reduced 87.68%
6,900 $205,000
Q3 2022

Nov 14, 2022

BUY
$37.92 - $63.74 $2.12 Million - $3.57 Million
56,009 New
56,009 $2.14 Million
Q1 2022

May 16, 2022

SELL
$49.85 - $96.11 $542,168 - $1.05 Million
-10,876 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$77.3 - $105.0 $3.37 Million - $4.58 Million
-43,610 Reduced 80.04%
10,876 $1.09 Million
Q3 2021

Nov 15, 2021

BUY
$74.87 - $110.87 $3.57 Million - $5.28 Million
47,663 Added 698.56%
54,486 $4.9 Million
Q2 2021

Aug 13, 2021

SELL
$66.8 - $100.45 $3.34 Million - $5.02 Million
-49,955 Reduced 87.98%
6,823 $629,000
Q1 2021

May 17, 2021

BUY
$59.3 - $183.85 $934,330 - $2.9 Million
15,756 Added 38.41%
56,778 $5.49 Million
Q4 2020

Feb 16, 2021

BUY
$31.01 - $52.1 $1.27 Million - $2.14 Million
41,022 New
41,022 $2.14 Million

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $592M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.